RNA transfection

Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Study of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients

Retrieved on: 
Monday, October 24, 2022
U.S. Securities and Exchange Commission, Uncertainty, RNA transfection, Medicine, Hospital, Acute myeloid leukemia, IND, AML, MD Anderson Cancer Center, Lymphoma, Weill Cornell Medicine, Annual report, NASDAQ, GRB2, Patient, RNA interference, Joe Byrd (Cherokee Nation Principal Chief), Lymphatic system, Scripps Health, Security (finance), STAT3, Clinical, Cornell University, Technology, University, Department, Patent, Safety, Intention, GLOBE, Clinical trial, Maintenance, Intellectual property, Life expectancy, Holding, COVID-19, BH3, Cancer, D.O, Pharmaceutical industry, Decitabine

We are delighted to have dosed the first patient in this key clinical trial.

Key Points: 
  • We are delighted to have dosed the first patient in this key clinical trial.
  • BP1002 targets the protein Bcl-2, which is responsible for driving cell survival in up to 60% of all cancers.
  • By targeting Bcl-2 at the mRNA level rather than the protein, BP1002 may overcome and prevent some of the mechanisms of resistance that affect venetoclax treatment.
  • The Companys second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia.

Vaxxinity Completes Enrollment in Pivotal Phase 3 Clinical Trial of UB-612 COVID-19 Vaccine Heterologous Booster Candidate and Initiates Rolling Submission for Provisional Approval in Australia

Retrieved on: 
Monday, October 24, 2022
U.S. Securities and Exchange Commission, Omicron, Migraine, RNA transfection, Efficiency, MHRA, Review, Vaccine, Immunity, Severe acute respiratory syndrome coronavirus 2, Annual report, Patient, Security (finance), Nasdaq, Technology, Private Securities Litigation Reform Act, TGA, Immunization, Immune system, Company, Health, CEO, Conditional sentence, Social media, Hypercholesterolemia, Safety, Ageing, GLOBE, COVID-19, Vaccination, Therapeutic Goods Administration, Forward-looking statement, Genta (company), CRO, Risk, Pharmaceutical industry

DALLAS, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that enrollment is complete for its global Phase 3 pivotal trial evaluating UB-612 as a heterologous booster vaccine to mRNA, adeno-vectored, and inactivated primary series vaccinations. The company remains on track to report topline data in the fourth quarter of 2022. In addition, the company has initiated a rolling submission to the Therapeutic Goods Administration (TGA) in Australia for provisional approval of its UB-612 COVID-19 vaccine as a heterologous boost after being granted provisional determination from the TGA in September 2022.

Key Points: 
  • In addition, the company has initiated a rolling submission to the Therapeutic Goods Administration (TGA) in Australia for provisional approval of its UB-612 COVID-19 vaccine as a heterologous boost after being granted provisional determination from the TGA in September 2022.
  • Completing enrollment in a pivotal COVID-19 vaccine trial is a tremendous accomplishment in todays environment and we are extremely grateful to all the participants, investigators, and CRO partners involved in this milestone.
  • We look forward to announcing topline immunogenicity data that will serve as the basis for future authorization applications, said Mei Mei Hu, CEO of Vaxxinity.
  • Our regulatory progress continues with the initiation of a rolling submission to the TGA in Australia, following the previously announced initiation of the rolling submission to MHRA in the UK .

BioNTech to Report Third Quarter 2022 Financial Results and Operational Update on November 7, 2022

Retrieved on: 
Monday, October 24, 2022
BNTX, Hoffmann-La Roche, BioNTech, Geneve 9640, RNA transfection, Telephone, Investor relations, Webcast, Nasdaq, Cancer, Infection, Company, CEST, Immunotherapy, EDT, GLOBE, Regeneron Pharmaceuticals, Pfizer, Genentech

Mainz, Germany, October 24, 2022 (GLOBE NEWSWIRE) BioNTech SE (Nasdaq: BNTX, BioNTech or the Company) will announce its financial results for the third quarter 2022 on Monday, November 7th, 2022.

Key Points: 
  • Mainz, Germany, October 24, 2022 (GLOBE NEWSWIRE) BioNTech SE (Nasdaq: BNTX, BioNTech or the Company) will announce its financial results for the third quarter 2022 on Monday, November 7th, 2022.
  • BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 8.00 a.m. EDT (2.00 p.m. CEST) to report its financial results and provide a corporate update for the third quarter 2022.
  • To access the live conference call via telephone, please register via this link .
  • The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals.

Arcturus Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 9, 2022

Retrieved on: 
Wednesday, October 26, 2022
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, LinkedIn, MicroRNA, RNA transfection, Therapy, Cystic Fibrosis Foundation, Vaccine, Severe acute respiratory syndrome coronavirus 2, Johnson & Johnson, Glycogen storage disease type III, Gene editing, Janssen Pharmaceuticals, RNA, Twitter, Diversified Specialty Institute Holdings, Inc., Nasdaq, Cystic fibrosis, Hepatitis B virus, III, ARCT, Patent, OTC, DNA, Messenger RNA, COVID-19, Baking

Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.

Key Points: 
  • Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.
  • Arcturus technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China and other countries).
  • Arcturus commitment to the development of novel RNA therapeutics has led to collaborations including, amongst others, Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., and the Cystic Fibrosis Foundation.
  • In addition, please connect with us on Twitter and LinkedIn .

Enveda Biosciences appoints industry leader Mark Deeg, M.D., Ph.D., as Chief Medical Officer

Retrieved on: 
Tuesday, October 25, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Data Management, Technology, Pharmacology, Kidney, RNA transfection, Therapy, University of Minnesota Medical School, IND, Lilly, Machine learning, Proteolysis targeting chimera, Metabolomics, Biotechnology, List of life sciences, Research, Multimedia, Eli Lilly and Company, Technology, Knowledge, University, Goal, Drug discovery, Industry, CEO, Pain, Eli Lilly, Chemistry, Clinical trial, Leadership, Pharmaceutical industry, Management, Medical device

Enveda Biosciences today announced the appointment of Mark Deeg, M.D., Ph.D., as the companys Chief Medical Officer.

Key Points: 
  • Enveda Biosciences today announced the appointment of Mark Deeg, M.D., Ph.D., as the companys Chief Medical Officer.
  • View the full release here: https://www.businesswire.com/news/home/20221025006040/en/
    Enveda Biosciences today announced the appointment of industry leader Mark Deeg, M.D., Ph.D., as the company's Chief Medical Officer.
  • (Photo: Business Wire)
    We are thrilled to welcome Mark Deeg to Enveda as our Chief Medical Officer, said Viswa Colluru, Ph.D., founder and CEO of Enveda.
  • Prior to this tenure at Cullgen, Mark held positions in medical and research leadership in companies focused on digital and mRNA therapies.

EMD Serono Highlights New Data for Evobrutinib, First BTKi to Demonstrate Sustained Clinical Benefit for People with RMS through Three and a Half Years of Treatment

Retrieved on: 
Wednesday, October 26, 2022
Health, Managed Care, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Immunology, Congress, Merck, RNA transfection, Multiple sclerosis, Science, OLE, MRI, University, Treatment, Hypoesthesia, Infertility, Antigen, Biomarker, SEL, MS, Gene editing, HIV disease progression rates, DBP, Inflammation, Learning, Senior, Cancer, Company, AFL, EMD, Phase, Central nervous system, Merck Millipore, BTK, Health care, Electronics, Lists of diseases, Intelligence, Research, Nerve, Microglia, CNS, ARR, European Committee of the Regions, Merck Serono, Disease, Life, Patient, EDSS, MD, Doctor of Philosophy, Â, RMS, University of Lille, Merck Group, COVID-19, Entrepreneurship, Neurodegeneration, Magnetic resonance imaging, Pharmaceutical industry, Vaccine, Medical imaging, Phosphorus, Biology, Health

In this longest-running and most extensive analysis of any BTK inhibitor in development for RMS, evobrutinib maintained disease stability for up to three and half years.

Key Points: 
  • In this longest-running and most extensive analysis of any BTK inhibitor in development for RMS, evobrutinib maintained disease stability for up to three and half years.
  • It also has the potential to directly address smoldering inflammation in RMS which contributes to the silent causes of disease progression.
  • It has previously shown promising results in targeting central inflammation, including through its modulatory effects on microglia.
  • Patients experienced sustained and ongoing reductions in blood NfL levels compared to the double-blind period (DBP) and OLE baseline values.

Merck Highlights New Data for Evobrutinib, First BTKi to Demonstrate Sustained Clinical Benefit for People with RMS through Three and a Half Years of Treatment

Retrieved on: 
Wednesday, October 26, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Immunology, Congress, RNA transfection, Science, Multiple sclerosis, OLE, MRI, University, Treatment, GMG, Hypoesthesia, Antigen, Biomarker, SEL, Neuromyelitis optica spectrum disorder, MS, Gene editing, HIV disease progression rates, DBP, NMOSD, Inflammation, Interferon beta-1a, Learning, Senior, Company, Neurology, AFL, Phase, Central nervous system, Merck Millipore, BTK, Electronics, Lists of diseases, Intelligence, Nerve, Microglia, CNS, ARR, European Committee of the Regions, SLE, Merck Serono, Disease, Lupus, Patient, EDSS, MD, Doctor of Philosophy, Â, Research, RMS, University of Lille, COVID-19, Entrepreneurship, Neurodegeneration, Magnetic resonance imaging, Pharmaceutical industry, Vaccine, Medical imaging, Phosphorus, Merck, Biology, Health

In this longest-running and most extensive analysis of any BTK inhibitor in development for RMS, evobrutinib maintained disease stability for up to three and half years.

Key Points: 
  • In this longest-running and most extensive analysis of any BTK inhibitor in development for RMS, evobrutinib maintained disease stability for up to three and half years.
  • It also has the potential to directly address smoldering inflammation in RMS which contributes to the silent causes of disease progression.
  • It has previously shown promising results in targeting central inflammation, including through its modulatory effects on microglia.
  • Patients experienced sustained and ongoing reductions in blood NfL levels compared to the double-blind period (DBP) and OLE baseline values.

Applied DNA to Establish North America’s First Enzymatic (Cell Free) Large-Scale cGMP DNA Manufacturing Capacity in Suffolk County, New York

Retrieved on: 
Monday, October 24, 2022
Other Manufacturing, Research, Genetics, Clinical Trials, Stem Cells, Manufacturing, Biotechnology, Pharmaceutical, Health, Science, Adoption, LinkedIn, Drug Quality and Security Act, RNA transfection, Medicine, SEC, Therapy, Contract research organization, Growth, CGMP, Cell, NASDAQ, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Annual report, Biotechnology, United States Department of Agriculture, Research, Twitter, RNA, Securities Act of 1933, Polymerase chain reaction, History, PCR, Private Securities Litigation Reform Act, Food, Goal, Good laboratory practice, Company, Industry, Health, CEO, Securities Exchange Act of 1934, Forward-looking statement, DNA, USDA, Calendar, FDA, United States Department of State, CRO, Leadership, Fine chemical, Vaccine, Medical device, Applied DNA Sciences

Steve Bellone, the Suffolk County Executive, stated, Long Islands DNA Corridor is the beating heart of the regions premier life sciences hub.

Key Points: 
  • Steve Bellone, the Suffolk County Executive, stated, Long Islands DNA Corridor is the beating heart of the regions premier life sciences hub.
  • The area continues to advance the forefront of modern medicine with local talent like Applied DNA, whose enzymatically produced DNA holds the potential to transform human health.
  • I am pleased to lend my Offices support to help it reach its goals for the benefit of us all.
  • Unlike large and capital-intensive plasmid-based DNA production facilities, the LinearDNA platform uses bench-top equipment to rapidly produce DNA in a minimal physical footprint.

Regen BioPharma, Inc. Explores the CAR-T Therapeutic Space

Retrieved on: 
Wednesday, October 26, 2022
SAN, News, RNA transfection, Neoplasm, CAGR, Lymphatic system, Cell, Quicc!, CAR, Cancer, PINK, Tumor microenvironment, Company, Patent, OTC, Lymphoma, Forward-looking statement, Leukemia, Lymphocyte, Degenerative disease, Regulation, Vaccine, Medical imaging

SAN DIEGO, Oct. 26, 2022 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) has filed several patents over the last year on multiple ways to improve CAR-T therapies currently being utilized in the treatment of cancers. 

Key Points: 
  • CAR-T have revolutionized the treatment of these cancers because they utilize the patient's own T cells to kill their own tumor.
  • By 2028, the market is expected to reach $25 billion, with a compound annual growth rate (CAGR) of 46.6%.
  • This makes CAR-T cells one of the fastest growing and potentially profitable therapeutic areas in oncology[1]."
  • Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.

SK bioscience and CEPI Sign Agreement to Develop mRNA Vaccines

Retrieved on: 
Tuesday, October 25, 2022
Lassa mammarenavirus, Bill, RNA transfection, Pandemic, Second, CEPI, GIA, Virus, CMV, Ministry of Health and Welfare (South Korea), JEV, Vaccine, Organization, Foundation, RSV, SK, RNA, MOHW, Equitable, Partnership, Technology, Infection, Epidemic, Company, Public health, Health, CEO, Ministry, Park Min-soo, Coalition, Control, COVID-19, USD, Policy, Pharmaceutical industry

USD for early development of mRNA vaccine platform to SK bioscience; up to a further 100 mil.

Key Points: 
  • USD for early development of mRNA vaccine platform to SK bioscience; up to a further 100 mil.
  • Under the agreement, SK bioscience will receive up to 140 million USD in R&D expenses from CEPI.
  • Earlier, SK bioscience had the partnership with the Bill & Melinda Gates Foundation in order to build the mRNA vaccine platform.
  • CEPI and SK bioscience are committed to enabling global equitable access to the vaccines they develop.